US-based Momenta Pharmaceuticals has revised its regulatory strategy in the US for its anti-FcRn antibody M923, which the company has proposed as a biosimilar to Humira, it was reported on Tuesday.
The company had indicated earlier that it planned to file a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the fourth quarter of 2018.
With the recent Abbvie agreement, Momenta will be able to commercialise M923 in the United States, pending regulatory approval, as early as November 20, 2023. The company has decided to delay the filing of the BLA, which is likely to reduce programme costs in 2019 without delaying M923's potential US market entry.
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data
Enhertu receives FDA approval for HER2+ solid tumours
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Lipogems enrols first patient in ARISE II US FDA IDE research study